AUTOLUS THERAPEUTICS PLC - AMERICAN DEPOSITARY SHA

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

09 Dec 2023 20:30:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

15 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces participation in upcoming conferences

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations

02 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

02 Nov 2023 07:11:50 By Nasdaq GlobeNewswire

Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

11 Oct 2023 08:07:12 By Nasdaq GlobeNewswire

Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

11 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress

03 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer

19 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023

18 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia

06 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces publication in Cancer Immunology Research

27 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director

20 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

16 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023

06 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO

02 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL

22 May 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA

12 May 2023 07:00:00 By Nasdaq GlobeNewswire